
A Matter Of Time: Estate Planning And Watch Collecting
In 2025, the global luxury watch market is thriving, with its value expected to grow from $104.21 billion to $158.19 billion by 2033; driven by demand for luxury brands like Rolex and Patek Philippe, as well as the continued popularity of smartwatches from Apple and Samsung. The U.S. market alone is projected to increase significantly. The pre-owned luxury watch market has stabilized after previous volatility, and new consumer demographics, especially Millennials and Gen Z, are influencing trends, with a focus on digital engagement and innovation. Aesthetic shifts include a growing demand for retro and vintage-inspired pieces, genderless styles, and bold designs.
With this strong market, and the fact that collecting watches is a multi-generational activity, I spoke to Edouard Caumon, the US Country Manager for Watchfinder & Co., about the complexities of the watch market, especially in the context of estate planning.
Edouard, with a rich background with prestigious watch companies like the Cartier and Richemont Group, highlighted the pivotal role of Watchfinder in authenticating and refurbishing pre-owned watches. He noted that pre-owned watches offer enthusiasts access to 95% of all watches ever produced, presenting a unique investment opportunity. Notably, 60%-64% of watches from brands like Rolex, Patek Philippe, and Audemars Piguet resell above their retail price, a testament to their enduring value.
The conversation also touched on the evolving interest in watch collecting among younger generations, particularly Gen Z. Edouard observed a growing trend of younger individuals viewing watches as viable investments, sometimes even favoring them over traditional assets like gold or real estate. This shift underscores the importance of understanding the asset potential of watches within estate planning.
When asked about the common pitfalls collectors and their advisors face in estate planning for collectors of watches, Edouard emphasized the necessity of authenticating and inspecting collections to avoid counterfeit parts, a crucial step in safeguarding their value. He shared anecdotes of a collector who purchased a watch for $90,000 from an online source, only to find out that the watch had a counterfeit movement and is, basically, worthless.
Cultural nuances also play a significant role in watch collecting. Edouard noted distinct differences among American, Asian, and European collectors, with varying approaches to secondary goods and trading cultures. American collectors are more accustomed to trading watches, that is buying then selling to acquire better or rarer watches. Asian buyers traditionally preferred buying new watches over pre-owned watches, but that is changing with the younger generation of collectors. European collectors tend not to sell watches but rather hand down watches to family and friends as a legacy. This variability highlights the importance of tailored strategies in estate planning to accommodate diverse preferences and market dynamics.
Accessorizing trends are reshaping the watch market, with smaller watches gaining popularity. Edouard shared innovative examples of watches being set into rings and cufflinks, reflecting a broader trend of personalization in luxury items. These evolving trends further complicate the valuation and planning processes for collectors looking to integrate watches into their estates.
Our conversation underscored the intricate relationship between the financial and the emotional value of collecting, and its impact on how people collect and therefore how their estate plans are impacted. Watches continue to hold significant financial and sentimental value, and may be one of the best performing investments in the years to come: understanding their role within an estate is crucial. By recognizing the importance of authenticity, cultural differences, and market trends, collectors can better navigate the complexities of integrating watches into their estate planning strategies.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
9 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
9 minutes ago
- Yahoo
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data